{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:00:50Z","timestamp":1776272450497,"version":"3.50.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose: The distribution and significance of caveolin 1 (CAV1) expression in different breast cell types and role in breast carcinogenesis remain poorly understood. Both tumor-suppressive and oncogenic roles have been proposed for this protein. The aims of this study were to characterize the distribution of CAV1 in normal breast, benign breast lesions, breast cancer precursors, and metaplastic breast carcinomas; to assess the prognostic significance of CAV1 expression in invasive breast carcinomas; and to define whether CAV1 gene amplification is the underlying genetic mechanism driving CAV1 overexpression in breast carcinomas.<\/jats:p>\n               <jats:p>Experimental Design: CAV1 distribution in frozen and paraffin-embedded whole tissue sections of normal breast was evaluated using immunohistochemistry, immunofluorescence, and immunoelectron microscopy. CAV1 expression was immunohistochemically analyzed in benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-based chemotherapy. In 25 cases, CAV1 gene amplification was assessed by chromogenic in situ hybridization.<\/jats:p>\n               <jats:p>Results: In normal breast, CAV1 was expressed in myoepithelial cells, endothelial cells, and a subset of fibroblasts. Luminal epithelial cells showed negligible staining. CAV1 was expressed in 90% of 39 metaplastic breast carcinomas and in 9.4% of 245 invasive breast cancers. In the later cohort, CAV1 expression was significantly associated with \u2018basal-like\u2019 immunophenotype and with shorter disease-free and overall survival on univariate analysis. CAV1 gene amplification was found in 13% of cases with strong CAV1 expression.<\/jats:p>\n               <jats:p>Conclusions: The concurrent CAV1 amplification and overexpression call into question its tumor-suppressive effects in basal-like breast carcinomas.<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-06-1371","type":"journal-article","created":{"date-parts":[[2007,1,3]],"date-time":"2007-01-03T15:52:37Z","timestamp":1167839557000},"page":"90-101","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":177,"title":["Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and <i>In situ<\/i> Hybridization Analysis"],"prefix":"10.1158","volume":"13","author":[{"given":"Kay","family":"Savage","sequence":"first","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Maryou B.K.","family":"Lambros","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"David","family":"Robertson","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Chris","family":"Jones","sequence":"additional","affiliation":[{"name":"2Section of Paediatric Oncology, Institute of Cancer Research, London, United Kingdom;"}]},{"given":"Alan","family":"Mackay","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Michelle","family":"James","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Jason L.","family":"Hornick","sequence":"additional","affiliation":[{"name":"3Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;"}]},{"given":"Emilio M.","family":"Pereira","sequence":"additional","affiliation":[{"name":"4Laborato\u0301rio Saloma\u0303o & Zoppi, Sa\u0303o Paulo, Brazil;"}]},{"given":"Fernanda","family":"Milanezi","sequence":"additional","affiliation":[{"name":"5Institute of Pathology and Molecular Immunology and Medical Faculty, University of Porto, Porto, Portugal; and"},{"name":"6Institute of Health and Life Sciences (Instituto de Investigac\u0327a\u0303o em Cie\u0302ncias da Vida e da Sau\u0301de), University of Minho, Braga, Portugal"}]},{"given":"Christopher D.M.","family":"Fletcher","sequence":"additional","affiliation":[{"name":"3Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;"}]},{"given":"Fernando C.","family":"Schmitt","sequence":"additional","affiliation":[{"name":"5Institute of Pathology and Molecular Immunology and Medical Faculty, University of Porto, Porto, Portugal; and"}]},{"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]},{"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[{"name":"1The Breakthrough Breast Cancer Research Centre and"}]}],"member":"1086","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"2022061105125219600_B1","doi-asserted-by":"crossref","unstructured":"Hnasko R, Lisanti MP. The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv\u20082003;3:445\u201364.","DOI":"10.1124\/mi.3.8.445"},{"key":"2022061105125219600_B2","doi-asserted-by":"crossref","unstructured":"Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol\u20082005;288:C494\u2013506.","DOI":"10.1152\/ajpcell.00458.2004"},{"key":"2022061105125219600_B3","doi-asserted-by":"crossref","unstructured":"Chen ST, Lin SY, Yeh KT, et al. Mutational, epigenetic, and expressional analyses of caveolin-1 gene in breast cancers. Int J Mol Med\u20082004;14:577\u201382.","DOI":"10.3892\/ijmm.14.4.577"},{"key":"2022061105125219600_B4","doi-asserted-by":"crossref","unstructured":"Engelman JA, Zhang XL, Lisanti MP. Sequence and detailed organization of the human caveolin-1 and -2 genes located near the D7S522 locus (7q31.1). Methylation of a CpG island in the 5\u2032 promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett\u20081999;448:221\u201330.","DOI":"10.1016\/S0014-5793(99)00365-8"},{"key":"2022061105125219600_B5","unstructured":"Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res\u20082001;61:2361\u20134."},{"key":"2022061105125219600_B6","doi-asserted-by":"crossref","unstructured":"Jones C, Mackay A, Grigoriadis A, et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res\u20082004;64:3037\u201345.","DOI":"10.1158\/0008-5472.CAN-03-2028"},{"key":"2022061105125219600_B7","doi-asserted-by":"crossref","unstructured":"Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (\u2212\/\u2212) null mice show mammary epithelial cell hyperplasia. Am J Pathol\u20082002;161:1357\u201369.","DOI":"10.1016\/S0002-9440(10)64412-4"},{"key":"2022061105125219600_B8","doi-asserted-by":"crossref","unstructured":"Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene\u20081998;16:1391\u20137.","DOI":"10.1038\/sj.onc.1201661"},{"key":"2022061105125219600_B9","doi-asserted-by":"crossref","unstructured":"Park SS, Kim JE, Kim YA, Kim YC, Kim SW. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology\u20082005;47:625\u201330.","DOI":"10.1111\/j.1365-2559.2005.02303.x"},{"key":"2022061105125219600_B10","doi-asserted-by":"crossref","unstructured":"Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat\u20082006;99:85\u201390.","DOI":"10.1007\/s10549-006-9184-1"},{"key":"2022061105125219600_B11","doi-asserted-by":"crossref","unstructured":"Sagara Y, Mimori K, Yoshinaga K, et al. Clinical significance of caveolin-1, caveolin-2, and HER2\/neu mRNA expression in human breast cancer. Br J Cancer\u20082004;91:959\u201365.","DOI":"10.1038\/sj.bjc.6602029"},{"key":"2022061105125219600_B12","doi-asserted-by":"crossref","unstructured":"Van den Eynden GG, Van Laere SJ, Van der Auwera I, et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat\u20082006;95:219\u201328.","DOI":"10.1007\/s10549-005-9002-1"},{"key":"2022061105125219600_B13","unstructured":"Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res\u20081998;4:1873\u201380."},{"key":"2022061105125219600_B14","unstructured":"Zou W, McDaneld L, Smith LM. Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res\u20082003;23:4581\u20136."},{"key":"2022061105125219600_B15","doi-asserted-by":"crossref","unstructured":"Charafe-Jauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene\u20082005;25:2273\u201384.","DOI":"10.1038\/sj.onc.1209254"},{"key":"2022061105125219600_B16","doi-asserted-by":"crossref","unstructured":"Hurlstone AF, Reid G, Reeves JR, et al. Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene\u20081999;18:1881\u201390.","DOI":"10.1038\/sj.onc.1202491"},{"key":"2022061105125219600_B17","doi-asserted-by":"crossref","unstructured":"Huang H, Reed CP, Mordi A, et al. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer\u20081999;24:48\u201355.","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.0.CO;2-V"},{"key":"2022061105125219600_B18","doi-asserted-by":"crossref","unstructured":"Nishizuka S, Tamura G, Terashima M, Satodate R. Commonly deleted region on the long arm of chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer\u20081997;76:1567\u201371.","DOI":"10.1038\/bjc.1997.598"},{"key":"2022061105125219600_B19","doi-asserted-by":"crossref","unstructured":"Han SY, Druck T, Huebner K. Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics\u20082003;81:105\u20137.","DOI":"10.1016\/S0888-7543(02)00029-0"},{"key":"2022061105125219600_B20","doi-asserted-by":"crossref","unstructured":"Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest\u20082001;108:1553\u201361.","DOI":"10.1172\/JCI200114611"},{"key":"2022061105125219600_B21","doi-asserted-by":"crossref","unstructured":"Razani B, Schlegel A, Lisanti MP. Caveolin proteins in signaling, oncogenic transformation, and muscular dystrophy. J Cell Sci\u20082000;113:2103\u20139.","DOI":"10.1242\/jcs.113.12.2103"},{"key":"2022061105125219600_B22","doi-asserted-by":"crossref","unstructured":"Sotgia F, Williams TM, Schubert W, et al. Caveolin-1 deficiency (\u2212\/\u2212) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol\u20082006;168:292\u2013309.","DOI":"10.2353\/ajpath.2006.050429"},{"key":"2022061105125219600_B23","doi-asserted-by":"crossref","unstructured":"Li T, Sotgia F, Vuolo MA, et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor \u03b1-positive status. Am J Pathol\u20082006;168:1998\u20132013.","DOI":"10.2353\/ajpath.2006.051089"},{"key":"2022061105125219600_B24","doi-asserted-by":"crossref","unstructured":"Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A\u20081999;96:12589\u201394.","DOI":"10.1073\/pnas.96.22.12589"},{"key":"2022061105125219600_B25","doi-asserted-by":"crossref","unstructured":"Reis-Filho JS, Milanezi F, Silva P, Schmitt FC. Maspin expression in myoepithelial tumors of the breast. Pathol Res Pract\u20082001;197:817\u201321.","DOI":"10.1078\/0344-0338-00165"},{"key":"2022061105125219600_B26","doi-asserted-by":"crossref","unstructured":"Mohsin SK, Zhang M, Clark GM, Craig Allred D. Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol\u20082003;199:432\u20135.","DOI":"10.1002\/path.1319"},{"key":"2022061105125219600_B27","doi-asserted-by":"crossref","unstructured":"Simpson PT, Gale T, Reis-Filho JS, et al. Distribution and significance of 14-3-3\u03c3, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. J Pathol\u20082004;202:274\u201385.","DOI":"10.1002\/path.1530"},{"key":"2022061105125219600_B28","doi-asserted-by":"crossref","unstructured":"Sunaga N, Miyajima K, Suzuki M, et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res\u20082004;64:4277\u201385.","DOI":"10.1158\/0008-5472.CAN-03-3941"},{"key":"2022061105125219600_B29","doi-asserted-by":"crossref","unstructured":"Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis\u20081999;4:233\u20137.","DOI":"10.1023\/A:1009612708099"},{"key":"2022061105125219600_B30","doi-asserted-by":"crossref","unstructured":"Rajjayabun PH, Garg S, Durkan GC, Charlton R, Robinson MC, Mellon JK. Caveolin-1 expression is associated with high-grade bladder cancer. Urology\u20082001;58:811\u20134.","DOI":"10.1016\/S0090-4295(01)01337-1"},{"key":"2022061105125219600_B31","doi-asserted-by":"crossref","unstructured":"Kato K, Hida Y, Miyamoto M, et al. Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer\u20082002;94:929\u201333.","DOI":"10.1002\/cncr.10329"},{"key":"2022061105125219600_B32","doi-asserted-by":"crossref","unstructured":"Ito Y, Yoshida H, Nakano K, et al. Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid. Br J Cancer\u20082002;86:912\u20136.","DOI":"10.1038\/sj.bjc.6600172"},{"key":"2022061105125219600_B33","doi-asserted-by":"crossref","unstructured":"Suzuoki M, Miyamoto M, Kato K, et al. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer\u20082002;87:1140\u20134.","DOI":"10.1038\/sj.bjc.6600619"},{"key":"2022061105125219600_B34","doi-asserted-by":"crossref","unstructured":"Jones C, Ford E, Gillett C, et al. Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res\u20082004;10:5988\u201397.","DOI":"10.1158\/1078-0432.CCR-03-0731"},{"key":"2022061105125219600_B35","doi-asserted-by":"crossref","unstructured":"Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology\u20082006;49:10\u201321.","DOI":"10.1111\/j.1365-2559.2006.02467.x"},{"key":"2022061105125219600_B36","doi-asserted-by":"crossref","unstructured":"Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Moinfar F. Metaplastic breast carcinomas: are they of myoepithelial differentiation?: immunohistochemical profile of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol\u20082005;29:347\u201353.","DOI":"10.1097\/01.pas.0000152133.60278.d2"},{"key":"2022061105125219600_B37","doi-asserted-by":"crossref","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology\u20081991;19:403\u201310.","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"2022061105125219600_B38","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res\u20082004;10:5367\u201374.","DOI":"10.1158\/1078-0432.CCR-04-0220"},{"key":"2022061105125219600_B39","doi-asserted-by":"crossref","unstructured":"Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic breast carcinomas show EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridisation analysis. Breast Cancer Res\u20082005;7:R1028\u201335.","DOI":"10.1186\/bcr1341"},{"key":"2022061105125219600_B40","doi-asserted-by":"crossref","unstructured":"Robertson D, Monaghan P, Clarke C, Atherton AJ. An appraisal of low-temperature embedding by progressive lowering of temperature into Lowicryl HM20 for immunocytochemical studies. J Microsc\u20081992;168:85\u2013100.","DOI":"10.1111\/j.1365-2818.1992.tb03253.x"},{"key":"2022061105125219600_B41","doi-asserted-by":"crossref","unstructured":"Reis-Filho JS, Savage K, Lambros MB, et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol\u20082006;19:999\u20131009.","DOI":"10.1038\/modpathol.3800621"},{"key":"2022061105125219600_B42","doi-asserted-by":"crossref","unstructured":"Lambros MB, Simpson PT, Jones C, et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest\u20082006;86:398\u2013408.","DOI":"10.1038\/labinvest.3700390"},{"key":"2022061105125219600_B43","doi-asserted-by":"crossref","unstructured":"Bhargava R, Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol\u20082005;18:1027\u201333.","DOI":"10.1038\/modpathol.3800438"},{"key":"2022061105125219600_B44","doi-asserted-by":"crossref","unstructured":"Clarke CL, Sandle J, Parry SC, Reis-Filho JS, O'Hare MJ, Lakhani SR. Cytokeratin 5\/6 in normal human breast: lack of evidence for a stem cell phenotype. J Pathol\u20082004;204:147\u201352.","DOI":"10.1002\/path.1647"},{"key":"2022061105125219600_B45","doi-asserted-by":"crossref","unstructured":"Pike LJ. Growth factor receptors, lipid rafts, and caveolae: an evolving story. Biochim Biophys Acta\u20082005;1746:260\u201373.","DOI":"10.1016\/j.bbamcr.2005.05.005"},{"key":"2022061105125219600_B46","doi-asserted-by":"crossref","unstructured":"Khan EM, Heidinger JM, Levy M, Lisanti MP, Ravid T, Goldkorn T. Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem\u20082006;281:14486\u201393.","DOI":"10.1074\/jbc.M509332200"},{"key":"2022061105125219600_B47","doi-asserted-by":"crossref","unstructured":"Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M, Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene\u20082004;23:6967\u201379.","DOI":"10.1038\/sj.onc.1207911"},{"key":"2022061105125219600_B48","doi-asserted-by":"crossref","unstructured":"Ringerike T, Blystad FD, Levy FO, Madshus IH, Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J Cell Sci\u20082002;115:1331\u201340.","DOI":"10.1242\/jcs.115.6.1331"},{"key":"2022061105125219600_B49","doi-asserted-by":"crossref","unstructured":"Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of \u03b2-catenin, and enhanced tumor cell invasion. Cancer Cell\u20082003;4:499\u2013515.","DOI":"10.1016\/S1535-6108(03)00304-0"},{"key":"2022061105125219600_B50","doi-asserted-by":"crossref","unstructured":"Pinto AE, Roque L, Rodrigues R, Andre S, Soares J. Frequent 7q gains in flow cytometric multiploid\/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation. J Clin Pathol\u20082006;59:367\u201372.","DOI":"10.1136\/jcp.2005.027722"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/1\/90\/1969316\/90.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/13\/1\/90\/1969316\/90.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T19:57:13Z","timestamp":1654977433000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/13\/1\/90\/193323\/Caveolin-1-Is-Overexpressed-and-Amplified-in-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,1,2]]},"published-print":{"date-parts":[[2007,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1371","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}